Your session is about to expire
← Back to Search
Copanlisib + Immunochemotherapy for Non-Hodgkin's Lymphoma (CHRONOS-4 Trial)
CHRONOS-4 Trial Summary
This trial is testing whether a new drug, copanlisib, is effective and safe when used with standard immunochemotherapy (R-B or R-CHOP) to treat patients with relapsed iNHL who have received 1-3 lines of treatment including rituximab-based immunochemotherapy and alkylating agents.
- Non-Hodgkin Lymphoma
CHRONOS-4 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CHRONOS-4 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for at least 3 more months.You have had or currently have a lung disease that affects your breathing, as determined by the doctor.Your high blood pressure is not well controlled even with the best possible medication.You have experienced a relapse or progression of your disease after receiving one to three previous lines of treatment, which may include medications like rituximab or obinutuzumab, as well as other therapies. The previous treatment must have been given for at least two months or two consecutive cycles, and may have included things like chemotherapy or a transplant. It's okay if you have been treated with other PI3K inhibitors before, as long as there was no resistance to those medications.
- Group 1: Placebo + R-B or R-CHOP / Arm 2
- Group 2: Copanlisib + R-B or R-CHOP / Arm 1
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other similar medical studies that have used Rituximab?
"Currently, there are 1536 ongoing studies researching Rituximab with 320 trials in Phase 3. While several of the trials for Rituximab are running out of in Majadahonda, Madrid, there are 54004 locations operating studies for Rituximab."
What is the official government stance on Rituximab?
"There is some evidence, from Phase 3 trials, to support the efficacy of Rituximab and multiple rounds of data have been collected to support its safety--giving it a score of 3."
Are there any available positions for volunteers in this experiment?
"This study, as detailed on clinicaltrials.gov, is not currently looking for new patients to enroll. The trial was first posted on January 6th, 2016 and last updated November 8th, 2022. There are 3325 other trials that are actively recruiting at this time."
How many study participants are involved in this research?
"Unfortunately, this trial is not looking for new patients at the moment. It was first posted on 1/6/2016 and most recently updated on 11/8/2022. However, there are alternative clinical trials that might be of interest; 1789 studies are actively recruiting participants with lymphoma, diffuse and 1536 studies involving Rituximab are also currently seeking patients."
For what treatments is Rituximab most often prescribed?
"Rituximab is the go-to treatment for leukemia. However, this medication can also be helpful in managing ophthalmia, sympathetic, therapeutic procedure, and lung cancers."
In how many different medical clinics is this medical study being run today?
"Presently, this clinical trial is welcoming patients at Memorial Sloan Kettering Cancer Center in New york, NY; SCL Health Research at St Joseph's Hospital Denver co in Denver, Colorado; Memorial Sloan Kettering Cancer Center- Bergen in Montvale, New jersey; and 16 other sites."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger